Understanding R/R PCNSL
In PCNSL, progression is likely and prognosis is poor1,2

What Is Primary Central Nervous System Lymphoma (PCNSL)?

PCNSL is a rare, highly malignant non-Hodgkin lymphoma (NHL) that primarily affects people aged >60 years. PCNSL accounts for1,3-5:

2%-3% of all NHL diagnoses

4% of CNS malignancies

  • In the US, about 0.45 cases per 100,000 people are diagnosed every year6
    • An estimated 1900 people will be diagnosed with PCNSL in 2023
  • The median age at diagnosis is 65 years, and older patients5,7:
    • Frequently present with comorbidities
    • Are less likely to tolerate treatment
    • Have a higher risk of neurotoxicity

pcnsl brochure

Download the brochure for more information you can share with your peers.

Relapsed and Refractory Disease Is Common in Patients With PCNSL8

Many patients will either be refractory to initial treatment (ie, stable or progressive disease during or at the end of first-line treatment) or relapse after initially responding to treatment.

About 1/3

of patients may be refractory to first-line
MTX-based chemotherapy regimens

Up to 60%

of patients who respond to first-line treatment may eventually relapse

Outcomes Are Particularly Poor for Patients With R/R PCNSL

Most patients whose disease progresses will not achieve a durable second remission.2

  • Most relapses occur within the first 2 years of initial diagnosis9
7.2 Months

Median overall survival time from first disease progression to death from any cause3

Outcomes among older patients have remained largely unchanged for decades due to10:

  • Poor performance status
  • Substantial comorbidities
  • No FDA-approved treatments indicated for R/R PCNSL
What are the challenges when navigating R/R PCNSL treatment?